Sep 7th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...
Nov 4th, 2020 - After promising 18-month outcomes in patients with proliferative lupus nephritis, obinutuzumab showed sustained benefits through 2 years of treatment for patients burdened with the rheumatic disease.
Sep 19th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program
Sep 19th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions
Sep 19th, 2020 - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The leading professional organisation for medical oncology
Sep 19th, 2020 - The COVID-19 pandemic has brought new challenges to clinical practice and research in oncology. ESMO is reporting on the current situation by news and KOLs experiences, and has gathered useful resources to keep medical oncologists updated.
Sep 19th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...
Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...
Sep 19th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.
Sep 19th, 2020 - Updates, guides, webinar series, recommendations, more.
Sep 19th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.
Sep 19th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.
Sep 19th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.
Sep 18th, 2020 - In this page you can find the articles related to COVID-19 disease in the context of cancer care management as published in the ESMO flagship journal, the Annals of Oncology and the ESMO Open.
Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.
Sep 18th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.
Sep 7th, 2020 - Please refer to the Frequently Asked Questions (FAQs) below for more information on the all-virtual ACR Convergence 2020. We will share more details as they become available in the coming weeks and months.
Aug 3rd, 2020 - This new edition of the World Federation of Hemophilia (WFH) guidelines for the management of hemophilia comes at an exciting time in the evolution of the diagnosis and treatment of this condition. Since the publication of the second edition in 2012, tremendous advances have been made in several aspects of the management of hemophilia. These include genetic assessment as well as therapy with ma...
JAMA Internal Medicine;
Jul 15th, 2020 - Since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection began in December 2019 in Wuhan, China, more than 6 million people have developed coronavirus disease 2019 (COVID-19), and more than 350 000 have died.1 Critical illness from COVID-19 in China, Italy, and other countries has strained intensive care unit (ICU) resources and produced a wide spectrum of sh...
Jul 10th, 2020 - Tumor mutational burden is considered a hallmark indicator of a tumor’s potential for response to immunotherapy. PD-1 checkpoint inhibitors such as pembrolizumab (Keytruda, Merck) and nivolumab (Opdivo, Bristol-Myers Squibb) have been shown to be more effective in treating tumors with high mutational burden. However, despite having only a moderate number of mutations, advanced clear cell ren...
Jul 9th, 2020 - In updated results of the pilot study, presented during the ASCO2020 Virtual Scientific Program, researchers showed that lisocabtagene maraleucel induced durable response as a second-line treatment in large B-cell non-Hodgkin lymphoma.
Jul 8th, 2020 - In a small sample, retreatment of patients with large B-cell lymphoma showed good response, notably in patients who had complete response on initial treatment, according to a poster presented at ASCO 2020 Virtual Scientific Program.
Jul 7th, 2020 - A study presented during the ASCO2020 Virtual Scientific Program showed ‘impressive’ use of immunotherapy for gestational trophoblastic disease, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.
Jul 7th, 2020 - Overall survival results from SOLO-2 showed patients with recurrent ovarian cancer and germline BRCA mutations added a year of life when treated with olaparib only, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.
Jul 7th, 2020 - Studies presented during the ASCO2020 Virtual Scientific Program showed the benefit of validated selection tools in pursuing surgical measures for ovarian cancer relapse, Ursula A. Matulonis, MD, of Dana Farber Cancer Institute, told Healio.
Jul 7th, 2020 - This essential study (Abstract 2003) highlights that health policy impacts cancer survival. It showed that age-adjusted mortality from cancer is worse in states that have not expanded access to Medicaid under the Affordable Care Act. There were 758 fewer cancer deaths in expansion states in 2017, and Hispanic populations had the greatest decrease in mortality under Medicaid expansion. This stud...
Jul 6th, 2020 - A novel CAR T-cell therapy targeting both CD19 and CD22 showed less toxicities than current CAR T-cell therapies while producing complete response with accepted regimens, according to a study presented at ASCO2020 Virtual Scientific Program.
Jul 6th, 2020 - The JAVELIN Bladder 100 study (LBA1) investigated the efficacy of maintenance avelumab following platinum-based chemotherapy compared to best supportive care for patients with metastatic urothelial cancer. In the trial, avelumab improved median overall survival by 21.4 months compared to 14.3 months with best supportive care. These data are practice changing, and the degree of benefit to this a...
Jul 3rd, 2020 - Head and neck cancers account for approximately 4% of all cancers in the United States1 and are the eighth most common cancer affecting men in the United States.2 The diagnosis of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) carries a poor prognosis, with an overall survival (OS) of approximately 1 year.
Jul 3rd, 2020 - DESKTOP III (Abstract 6000) is a prospective, multicenter, randomized phase III study of > 400 patients with platinum-sensitive, recurrent ovarian cancer that demonstrated a clinically meaningful 7.7 month improvement in median overall survival with secondary cytoreductive surgery (53.7 months) compared with no surgery (46 months).
Jul 3rd, 2020 - The phase III HERO trial (Abstract 5602) investigated the results of relugolix, an orally bioavailable GnRH receptor antagonist, for patients with advanced prostate cancer. Treatment with relugolix resulted in superiority over leuprolide in achieving sustained testosterone suppression. Additionally, treatment was associated with faster testosterone recovery and decreased major adverse cardiovas...
Jul 2nd, 2020 - Donafenib, a deuterated derivative of sorafenib, was tested against sorafenib in the frontline setting in hepatitis B– associated hepatocellular carcinoma (HCC) in a large, multi-institutional study in China (Abstract 4506).
Jul 2nd, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-cell therapy, with 4-1BB costimulatory domain and CD3Z T-cell activation domain.
Clinical Infectious Diseases; Monica Fung MD, MPH et. al.
Jun 27th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features and outcomes of COVID-19 among immunosuppressed patients, who are at presumed risk for more severe disease but who may also have decreased detrimental inflammatory responses, are no...
Jun 25th, 2020 - There used to be a paucity of options for managing advanced renal cell cancer (RCC) with a high toxicity profile including traditional chemotherapy, interferon, and interleukins. With the advent of tyrosine kinase inhibitors (TKIs) in 2007 followed by immunotherapy over the past few years, a paradigm shift emerged in managing this increasingly prevalent disease with its associated high morbidit...
Jun 25th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, MD, of the University of North Carolina School of Medicine, reviewed the most influential lung cancer research presented during the ASCO20 Virtual Sci...
Jun 25th, 2020 - The ASCO20 Virtual Scientific Program featured a variety of important and innovative breast cancer research. The following are some of the studies with potential to significantly impact clinical practice and patient outcomes, as selected by ASCO Daily News Expert Panel member Arielle Heeke, MD, of the Levine Cancer Institute.
Jun 24th, 2020 - The report on ADAURA during the ASCO20 Virtual Scientific Program Plenary Session surprised many, first because the initial data readout for the phase III trial was not planned until 2022 and second because of the strength of the disclosed data (Abstract LBA5). Early unblinding of the results revealed an 83% reduction in the risk of disease recurrence or death with use of adjuvant osimertinib c...
Jun 24th, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...
Jun 24th, 2020 - Long-awaited results from the randomized, phase III KEYNOTE-177 trial provide strong support for using single-agent pembrolizumab instead of a chemotherapy-based regimen in patients newly diagnosed with metastatic colorectal cancer (mCRC) featuring high-level microsatellite instability (MSI-H) or deficient mismatch repair (dMMR; Abstract LBA4).
Jun 24th, 2020 - For patients with stage IV metastatic breast cancer and an intact primary tumor (ITP), the early initiation of locoregional treatment (LRT) was not associated with longer survival or improvements in health-related quality of life (HRQoL) compared with systemic therapy alone, according to a phase III clinical trial (Abstract LBA2). These findings appear to add to a robust evidence base that sugg...
Jun 24th, 2020 - A switch maintenance therapy approach using the immune checkpoint inhibitor avelumab in patients with advanced urothelial carcinoma (UC) who had not progressed after induction platinum-based chemotherapy offered significantly improved survival outcomes, according to results of the JAVELIN Bladder 100 trial (Abstract LBA1). The study, which was the first UC study ever presented during an ASCO An...
Jun 8th, 2020 - The addition of trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) in the NRG Oncology clinical trial NSABP B-43. The trial did find a modest (19%) reduction in the rate of recurrence among women who received trastuzumab, but this difference was not stati...
Jun 5th, 2020 - The RET inhibitor pralsetinib showed activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the phase I/II ARROW trial, presented by Vivek Subbiah, MD, and colleagues during the ASCO20 Virtual Scientific Program (Abstract 109).
Jun 5th, 2020 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah presented the first outcomes evaluation of an adult oncology hospital-at-home program during the ASCO20 Virtual Scientific Program (Abstract 7000). The study evaluated patients participating in HCI's Huntsman at Home program. The data demonstrated strong evidence for the benefits of this care model, showing improved patien...
Jun 2nd, 2020 - Genetic testing for cancer risk can significantly improve the prevention or treatment of hereditary cancers, but studies have shown that people who might have a genetic risk often don't get tested. A collaborative team of researchers have tested a possible solution through a clinical trial aimed at making genetic testing more accessible. The trial, called MAGENTA (Making GENetic Testing Accessi...
Jun 2nd, 2020 - Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however, activity between the treatments was similar in patients. These results were recently presented by Joyce ...
Jun 1st, 2020 - Data from clinical efficacy and biomarker analyses conducted for the single-arm phase II PrE0505 study of the initial treatment of patients with malignant pleural mesothelioma were presented by Patrick Forde, MB, BCh, and colleagues during the Lung Cancer Oral Abstract Session at the ASCO20 Virtual Scientific Program (Abstract 9003). The trial evaluated the addition of durvalumab, an immune che...
Jun 1st, 2020 - The combination of carfilzomib, lenalidomide, and dexamethasone (KRd) did not show superior efficacy in patients with newly diagnosed myeloma absent a high-risk disease prognosis, compared with the standard of care: bortezomib, lenalidomide, and dexamethasone (VRd). Data from a planned interim analysis for efficacy and toxicity in the randomized phase III ENDURANCE trial were presented in the P...
Jun 1st, 2020 - Alberto F. Sobrero, MD, of the Ospedale San Martino, discusses final results of the IDEA study, which supported the use of 3 months of adjuvant CAPOX, vs 6 months, for most patients with stage III colon cancer. The shorter treatment duration reduced toxicity, inconvenience, and cost (Abstract 4004).
Jun 1st, 2020 - Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).
Jun 1st, 2020 - Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses phase III results of the HERO study, which showed relugolix achieved castration as early as day 4 and was superior to leuprolide in sustained testosterone suppression, testosterone recovery after discontinuation, and reduction in cardiovascular side effects (Abstract 5602).
Jun 1st, 2020 - Thierry André, MD, of Hôpital Saint-Antoine, discusses the phase III results from KEYNOTE-177, which showed that, compared with standard chemotherapy of FOLFOX or FOLFIRI, pembrolizumab doubled median progression-free survival, from 8.2 months to 16.5 months, in patients with microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer (Abstract LBA4).
Jun 1st, 2020 - Rana R. McKay, MD, of the University of California, San Diego, discusses the results of a phase II trial of intense neoadjuvant hormone therapy followed by radical prostatectomy in men with high-risk prostate cancer. The data show that 21% of patients had a favorable pathologic response (Abstract 5503).
Jun 1st, 2020 - Early local therapy did not prolong survival among women with de novo metastatic breast cancer and intact primary tumors, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.
Jun 1st, 2020 - Adjuvant atezolizumab failed to extend DFS compared with observation for patients with high-risk muscle-invasive urothelial carcinoma, according to randomized phase 3 study results presented during the ASCO20 Virtual Scientific Program.
Jun 1st, 2020 - An allogeneic chimeric antigen T-cell therapy plus an anti-CD52 monoclonal antibody appeared safe for certain patients with large B-cell or follicular lymphoma, according to study data presented during the ASCO20 Virtual Scientific Program.
Jun 1st, 2020 - share to facebook share to twitter share to linkedin email article The combination of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone, or VRd, successfully fended off a direct challenge to its position as standard of care in newly diagnosed multiple myeloma.
Jun 1st, 2020 - Adding tucatinib (Tukysa) to a trastuzumab-capecitabine (Herceptin-Xeloda) regimen significantly improved central nervous system (CNS) outcomes versus placebo plus trastuzumab-capecitabine in patients with HER2-positive metastatic breast cancer and brain metastases at baseline, researchers reported.
Jun 1st, 2020 - Combination therapy with the isocitrate dehydrogenase 1 (IDH1) inhibitor ivosenidib plus the BCL2 inhibitor venetoclax with or without the chemotherapeutic agent azacitidine showed activity in patients with IDH1-mutated acute myeloid leukemia (AML) in a phase Ib/II trial. The results of the study—presented by Lachowiez et al during the Hematologic Malignancies Oral Abstract Session of the ASCO2...
Jun 1st, 2020 - Women who present at diagnosis with advanced breast cancer have faced an unanswered question: will local therapy, consisting of surgery and radiation to the tumor in the breast, prolong survival compared to the traditional treatment of systemic treatment alone?
Jun 1st, 2020 - Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated clear cell renal cell carcinoma as well as responses in other VHL-related lesions (Abstract 5003).
Jun 1st, 2020 - Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual presentations.
Jun 1st, 2020 - Cynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).
Jun 1st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall response rates compared with twice-weekly bortezomib and dexamethasone in patients previously treated for multiple myeloma (Abstract 8501).
Jun 1st, 2020 - Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, locoregional treatment of the primary tumor did not offer a greater survival benefit than systemic therapy (Abstract LBA2).
Jun 1st, 2020 - Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-free survival and might contribute to long-term survival (Abstract 6001).
May 31st, 2020 - The phase 3 IMvigor010 trial comparing adjuvant atezolizumab (Tecentriq) with observation in patients with muscle-invasive urothelial carcinoma (MIUC) failed to meet its primary endpoint of disease-free survival (DFS), according to primary analysis data presented at the 2020 ASCO Virtual Scientific Program.
May 31st, 2020 - In the phase 2 trial EMPOWER-CSCC-1 (NCT02760498), up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response (DOR) for cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
May 31st, 2020 - Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology at Rigshopitalet–Copenhagen University Hospital in Denmark and medical director of the Nordic Society of Gynaecological Oncology, discusses the final survival data from the randomized phase 2 NSGO-AVANOVA2/ENGOT-OV24 study, which evaluated the combination or niraparib (Zejula) plus bevacizumab (Avastin) versus niraparib alon...
May 31st, 2020 - Avelumab switch maintenance prolonged OS among patients with advanced urothelial carcinoma whose disease did not progress after first-line chemotherapy, according to study results presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Axitinib significantly extended PFS among patients with recurred or metastatic adenoid cystic carcinoma, according to results of a randomized phase 2 study presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Idecabtagene vicleucel induced responses in nearly three-quarters of patients with relapsed or refractory multiple myeloma, according to initial results of the phase 2 KarMMa trial presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Axicabtagene ciloleucel induced a 93% response rate among patients with relapsed or refractory indolent non-Hodgkin lymphoma, according to interim results of the phase 2 ZUMA-5 trial presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Progressing cancer appeared independently associated with increased risk for death among a cohort of patients with malignancies and COVID-19, according to study results presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - Doxorubicin in combination with trabectedin appeared to be an effective and safe first-line therapy for metastatic leiomyosarcoma, according to results of the phase 2 LMS-02 study presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.
May 31st, 2020 - share to facebook share to twitter share to linkedin email article Including the XPO1 inhibitor selinexor (Xpovio) in a weekly bortezomib (Velcade) regimen improved oncologic outcomes and reduced rates of neuropathy in relapsed or refractory multiple myeloma, the phase III BOSTON trial showed.
May 31st, 2020 - Almost 100% of patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) responded to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta), data from an ongoing study showed.
May 31st, 2020 - Early initiation of locoregional treatment (LRT) of an intact primary tumor (IPT) in women with de novo stage IV metastatic breast cancer does not appear to prolong survival or improve health-related quality of life (HRQoL) compared with systemic therapy alone, according to a new study (Abstract LBA2). Seema A. Khan, MD, of the Northwestern Memorial Hospital, presented these findings during the...
May 31st, 2020 - Baseline and posttreatment circulating tumor DNA (ctDNA) positivity was associated with worse radiologic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to a correlative analysis from the randomized phase 2 A.MARTIN trial presented at the 2020 Virtual Scientific Meeting.
May 31st, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy regardless of prior therapy, according to data from a pooled analysis of patients treated on the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C20...
May 31st, 2020 - The combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features, according to findings from the phase 1b COSMIC-021 trial presented during the 2020 ASCO Virtual Scientific Program.
May 31st, 2020 - Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to results of a preplanned final overall survival (OS) analysis of the phase III ARAMIS trial, which were presented during the 2020 ASCO Virtual Scientific Program.
May 31st, 2020 - Pyrotinib plus capecitabine achieved a better progression-free survival (PFS) than lapatinib (Tykerb) plus capecitabine in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab and chemotherapy. Results from the phase 3 PHOEBE trial (NCT03080805) with were presented as part of the 2020 ASCO Virtual Scientific Program.
May 31st, 2020 - The use of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) may continue as a standard of care in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, based on results of a poster presented during the 2020 American Society of Clinical Oncology Virt...
May 31st, 2020 - We are recapping some of the top news that have been presented during the conference—and soon we’ll speak with Drs Brian Rini and Christopher Sweeney on some significant data being presented in genitourinary cancers, as well as Dr Roy Herbst on some practice-changing lung cancer studies.
May 31st, 2020 - According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib (Cabometyx) and atezolizumab (Tecentriq) demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with high-risk clinical features.
May 31st, 2020 - Circulating tumor DNA (ctDNA) showing positivity in patients with metastatic castration-resistant prostate cancer (mCRPC) at baseline and posttreatment in the randomized phase 2 A.MARTIN trial was associated with worse radiologic progression-free survival (rPFS), according to a correlative analysis presented at the 2020 Virtual Scientific Meeting.
May 31st, 2020 - Patients with nonmetastatic castration-resistant prostate cancer (CRPC) receiving darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) had a 31% reduction for the risk of death compared with placebo and ADT, according to the results of the phase 3 ARAMIS trial’s preplanned final overall survival (OS) analysis presented during the 2020 ASCO Virtual Scientific Program.
May 31st, 2020 - Adjuvant treatment with anti–PD-L1 therapy demonstrated a numerically increased but not statistically significant improvement in disease-free survival (DFS) compared with observation in patients with muscle-invasive urothelial carcinoma (MIUC) in a primary analysis presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program. DFS was the primary end point of the IMvigo...
May 31st, 2020 - Durable clinical activity was demonstrated with tepotinib, an oral, highly selective MET inhibitor, in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) and a MET exon 14 (METex14) skipping mutation identified through liquid or tissue biopsy. This data was from the phase 2 VISION trial (NCT02864992) presented during the at the 2020 Virtual Scientific Meeting and pu...
May 31st, 2020 - Three-year follow-up data from the phase 2 EMPOWER-CSCC-1 trial (NCT02760498) demonstrated a clinically meaningful survival and duration of response (DOR) improvement with cemiplimab-rwlc (Libtayo) in patients with advanced cutaneous squamous cell carcinoma (CSCC).
May 31st, 2020 - Pralsetinib (BLU-667) demonstrated significant efficacy across various advanced solid tumor types harboring RET alterations, including in patients with difficult-to-treat cancers, according to findings from a subgroup of the ongoing phase 1/2 ARROW trial (NCT03037385) presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
May 31st, 2020 - Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel (Jevtana) over abiraterone acetate (Zytiga) or enzalutamide (Xtandi) as a standard treatment in men with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with docetaxel and either of those 2 androgen receptor (AR)-targeted agents, accor...
May 31st, 2020 - Patients with ALK-positive non–small cell lung cancer (NSCLC) showed clinically meaningful improvement in overall survival (OS) when receiving alectinib (Alecensa), a highly selective second-generation TKI, versus those treated with crizotinib (Xalkori), according to updated data from the pivotal phase 3 ALEX trial presented at the 2020 ASCO Virtual Scientific Program.
May 30th, 2020 - Findings from a 5-year analysis of the phase 3 COMBI-AD trial validated the long-term benefit of adjuvant dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with resected, stage III BRAF V600E/K-mutant melanoma.
May 30th, 2020 - Brian A. Van Tine, MD, PhD, associate professor in the Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.
May 30th, 2020 - The combination of encorafenib (Braftovi) and binimetinib (Mektovi) demonstrated continuing benefit in overall survival (OS) and progression-free survival (PFS) for patients with BRAF V600–mutant melanoma, according to an updated analysis of the COLUMBUS (NCT01909453) trial during a poster presentation at the 2020 American Society of Clinical Oncology Virtual Scientific Program.